Life 17 (3), 169181
PMID: 3569763 DOI: 10.1016/0016-5085(87)90619-6 Runde TJ, Nappe TM (2023): Salicylates Toxicity
Phase II Phase II is a continuation of the activities started in phase I but on a larger scale and budget (and can also sometimes be accessed directly in Direct to Phase II or D2P2 solicitations)
Clinical and experimental studies support this framework: Peripheral pro-inflammatory cytokines, such as IL-6, may disrupt the BBB and activate central inflammation, potentially leading to cognitive impairments (134)
WQS regression model, BKMR model, and mediation analysis adjusted for all covariates, implemented via R 4.2.3 ( with gWQS (version 3.0.5), bkmr (version 0.2.2), and mediation (version 4.5.0) packages, alongside Empower Stats ( X & Y Solutions, Inc., Boston, MA)
TB-500 demonstrates a favorable safety profile in preclinical studies and in the available Phase 2 trials of Thymosin Beta-4